24 Jul Date July 24, 2025 Author TelaraPharma Tags Arch Biopartners, renal injury, The Cilastatin project Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) We at Telara Pharma are thrilled to see our partner Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) announce the start of patient r...